P
rogress in basic science research for rare diseases is dependent on the availability of human tissue for research. A specialty such as paediatric surgery encompasses many rare conditions whose aetiology and pathophysiology are poorly understood; subsequently, uncertainty exists regarding optimal patient management. Medical research in paediatrics lags behind that of adult medicine. Children are a smaller patient group and low population samples hinder the power and validity of randomised controlled trials. In addition, complex ethical issues surround the consent process involving children, which make clinical studies in this population more challenging. 1 An important element for continuing research is tissue-sampling both of pathological and normal control specimens. The value of storing tissue for research can be magnified if stored in biobanks, as the specimens and data can be accessed and used by multiple researchers for cross-purpose studies. Biobanks, used since the late 1990s, are large collections of biological specimens and biological data, amassed for basic science and translational research. They are a powerful tool that has become increasingly vital for medical research and, in particular, for rarer conditions.
In the UK, the Human Tissue Act 2004 legislates for the removal, storage and use of human tissue for research, subject to patient or parental consent. Biobanking requires similar regulatory procedures, with extra complexity, which can create additional barriers for their use. Ethical issues include informed consent and the management of incidental findings.
2 This highlights the importance for clinicians to be well-informed about biobanking such that they can provide patients and parents with a sufficient explanation and obtain adequate consent for use of tissue for research. Surgeons are often best placed to obtain consent for research, not only because they are involved in performing the surgical procedure that removes tissue but also because they are actively involved in patient care and management.
We aim to raise clinicians' awareness of the value of biobanks and to highlight the surgeon's role in increasing availability of tissue samples for biobanks. We present an audit that evaluates the effectiveness of paediatric surgeons in the process of consenting parents to donate tissue for research.
METHODS

Consent process for biobanking
The processing of consent is as follows:
• Preoperative: consent by surgeon.
• Postoperative: consent form (copy) included with specimen.
• Histopathology department: registration and processing of specimen.
• Human-tissue bank: processing of consent, storage and provision of access to specimen for research.
All standard procedural consent forms at our institution have an embedded section for signed patient or parent consent for 'potential for research on specimens taken for diagnostic purpose' (ie permission for biobanking) and include a record of opting out of research. Clinicians can use this section at their own discretion. Tissue specimens should be accompanied with a copy of the procedural consent form as part of theatre sign-out procedure and sent to the histopathology department. The histopathology department registers the sample and any accompanying procedural consent form. The Human Tissue Resource Centre (Barts Health Biobank) further processes consent forms valid for potential research and biobanking.
Patients and data collection
An audit was performed by reviewing 250 consecutive tissue specimens from the paediatric surgery department between March and December 2014 at the Royal London Hospital (part of Barts Health NHS Trust). After initial analysis and intervention, further consecutive samples were reviewed on a monthly basis for five months. Data were collected from a prospectively maintained histopathology database (WinPath) and the Human Tissue Research Centre audit database of consent forms. Approval for this audit was gained through the hospital's clinical effectiveness unit (ID number 5647).
Outcome measures
The primary outcome measure was the proportion of specimens available for research and biobanking. Other outcome measures included the number of procedural consent forms collected, consent forms completed, and patients or parents declining biobanking.
Intervention for improvement
Following the initial audit cycle, a professional behaviour modification programme was implemented. This included one educational session for all surgeons (consultant and registrars) within the paediatric surgery department on the embedded consent section for tissue for research, the processing of the consent form, and biobanking at our institution. Weekly email reminders were sent during a one-month period in January 2015 in advance of monthly re-auditing of performance.
Statistics
Data were compared using Fisher's exact test. Analysis was performed using GraphPad Prism® version 5.01 for Windows. P-values greater than 0.05 were considered significant.
RESULTS
Initial audit of performance
Before the behaviour change intervention, 79% (198/250) of consent forms were available to the histopathology department and 4% (8/198 ) of forms that reached the histopathology laboratory were valid for biobanking. Overall, 3% (8/250) of resected specimens were available for research. No parents declined biobanking of collected tissue.
Performance following intervention
One month after the implementation of the professional behavioural programme, 31 specimens were collected and 84% (26/31) of consent forms were received; 73% (19/26) of forms were adequately completed. Overall, 61% (19/31) of resected specimens were available for research. After surgeon education, the numbers of specimens available for research had increased from 3% to 61% (p<0.0001).
Performance was assessed for four further months and is summarised in Table 1 and Figure 1 . The trend in the following four months was a decrease in performance, compared with the first month following intervention. However, the proportion of consent forms available for biobanking each month remained a significant improvement compared with the pre-intervention period (p<0.001).
Of the consent forms completed, 3/55 (5%) showed that the parent declined biobanking in the post-intervention period; this was not significantly different from the pre-intervention audit (p=1.0).
DISCUSSION
The paediatric population is under-represented in medical research but it is essential to maintain the same level of good quality studies.
3 Tissue collection is essential for medical research to advance our understanding of the genetics, pathophysiology and pharmacological treatments for congenital and acquired conditions. Obtaining adequate tissues samples can be difficult, especially for rare pathologies.
To overcome this obstacle, biobanks facilitate pooling and sharing of specimens for research, allowing researchers to obtain larger sample numbers to raise statistical power of studies.
4
Multiple biobanks may be required. A study on the genomic architecture of breast tumours, for example, used five biobanks to achieve adequate numbers. 5 It is accepted that a single biobank often cannot provide sufficient samples to capture the full spectrum of disease and an integrated networks of biobanks is required to achieve these numbers.
Research in all fields of paediatrics is arguably more challenging than that in the adult population. The pharmaceutical industry often lacks interest because the market is small and non-profitable.
1 Other barriers to paediatric research include the lack of a suitable infrastructure for conducting clinical trials in children, difficulties in trial design, gaining the assent of a minor, privacy protection, return of results and ethical concerns regarding adequate consent.
6
The ethical and legal issues surrounding paediatric biobanks in general are extensive and complicated. The relevant literature focuses on two main issues: the right to consent to participation and how to manage individual results with implications for the participants' current, future or a relative's health. Allowing for informed consent and complying with data protection regulations can be challenging, as the purposes and results of subsequent research are not always known at the time of initial biobanking consent. Similarly, the amount of time that the information will be held is not always specified.
Parental consent to participation is the mainstay of biobanking consent. However, consideration must be given to the ethics behind legal representatives giving consent for the future use of tissue and at what point a child becomes able to fully comprehend the implications of tissue donation and thus able to consent for themselves. The ability of children to either opt out of biobanks, or indeed to give explicit consent, requires them to be contacted in the future. How and when this ought to happen is a point of controversy. A fixed age threshold would be most feasible in cases of a one-time donation, whereas situations involving a continuing relationship between the participant and researcher would allow a more detailed assessment of the child's ability to give informed consent.
Managing individual results is a challenging issue; the extent of the results returned, the method, and the privacy rights of the child must be considered. A panel of experts in the Netherlands suggested that results returned 'should not extend clinically actionable immediate health risks'.
7 For example, in genetic studies by withholding information regarding late-onset conditions the privacy of the child is theoretically protected but the management of the availability of this information at a later point must also be considered. Table 1 Comparison pre-and post-intervention: the number of specimens, consent forms collected and completed, opt-out rate, proportion of specimens for biobanking 0 P r ei n t e r v e n t i o n M o n t h four groups, which determined the information they received: none, all, binary (choice between none or all) and granular (using a preference setting tool). The granular group had greatest satisfaction with the process and this gives weight to the use of these preference tools in the clinical setting.
8
Overall, the benefits of biobanking must be weighed against the potential harm. Although the potential for personal benefit from tissue donation is low, it has been suggested that altruistic benefit alone can justify participation. 9 More commonly accepted is the concept of group benefit, whereby other children in a similar situation can benefit from improved diagnostic or therapeutic advances resulting from biobanking. 10 However, these benefits must be deemed to outweigh the potential harm of the privacy sensitive information. Possible implications of misuse of genetic data could extend to discrimination, stigmatism, psychological distress and impaired access to employment or insurance depending on the nature of the information.
11
As such, paediatric biobanks require distinct policies to account for the needs of children, their general incapacity and their intellectual development throughout the life of the biobank.
12 Consideration should also be given to the potential financial conflict that exists regarding the cost of establishing and maintaining biobanks with the need to obtain financial benefit from their use. In the absence of central funding, commercial imperative may conflict with the altruism of the individual. Our study highlights how human factors can have an effect on the efficacy of tissue collection for biobanks, as demonstrated during the process of obtaining consent from the patient or parent and administrative tasks by the clinical team.
Patient and parental awareness and education is vital for informed consent to tissue donation. Our study showed only 3% of parents opting out of contributing towards biobanks. Other studies have shown that the public, patients and parents are overall supportive of biobanks and tissue research.
13-15 Salveterra et al 16 interviewed a focus group of parents of sick children to explore their views towards tissue collection. The group confirmed a willing attitude of parents to enrol their children in biobank-based studies, regardless of the nature of the disease affecting the child. The main motivations for contribution were 'helping others' and 'research advances'. The authors believed that parents were generally not worried about privacy protection and supported the children's participation in donation decisions. A systematic review of 48 studies (involving surveys, focus groups, interviews, consent form analyses) showed that overall willingness for data to be shared was high.
17
However, this was lower among individuals from under-represented minorities, individuals with privacy and confidentiality concerns, and when pharmaceutical companies had access to data. Furthermore, many studies exploring the opinions of the general public may underestimate the positive attitudes as it has been shown that adolescents with pathology and their parents have a higher willingness to participate in biobanks than healthy teenagers.
18
An important potential barrier lies with the clinician in the consent process. Primarily, clinicians must ask for consent for tissue donation. Reasons for not consenting patients and parents include clinicians not being aware of this opportunity, time pressures and forgetting or not wanting to cause distress to parents at what is often a stressful and upsetting time for parents of children requiring surgery. In a survey of delegates at a paediatric palliative care conference, more than 50% of the participants reported that 'time and other resources' were a barrier to their research. 19 Another evaluation by a group in Toronto assessed 4,007 tissue collection consent forms and found that 32% were not signed (ie the patient had not been asked). Of the 68% signed consent forms, 10 patients (0.3%) denied consent. 20 Interestingly, this group found that there was a greater patient agreement rate (95.1%) when their institution's pathology or research coordinators were involved in the consent process. This suggests that specific training and having more dedicated time for consent can maximise patient agreement to biobanking. Embedded consent forms for biobanking have been shown to increase consent rates compared with standalone biobank consent forms (66% compared with 31%). 21 The Royal
London Hospital uses an embedded consent form whereby consent for biobanking is within the procedural consent form, with the aim of prompting clinicians and saving time for consenting. Our study has shown that simple behaviour change methods, such as surgeon education reinforced with regular reminders, led to a significant increase in the number of specimens available for research.
The main limiting factors of the study are sample size and duration of data collection; 250 consent forms were reviewed before but only 31 in the first month after intervention. The concepts demonstrated here, namely educating clinicians about the importance of consenting and the use of tissue samples in research, can in turn advance the education of patients and parents and improve informed consent. It is possible that the effect of the behaviour-change method could fade over time if the education and reminders did not continue. However, recent research using behaviour-change approaches implemented in general practices have shown sustainability of such methods. A trial tracked the prescribing habits of general practitioners up to six months after receiving an educational letter regarding prescribing practice and showed sustained behaviour change at six months after the single piece of information intervention. 22 Although we monitored the effect of the behaviour change method over 5 months, a longer assessment of the results would allow better evaluation of the sustained change and rate of diminishing effects over time from the intervention. Unfortunately, there is a finite time available for surgeons to adequately consent patients -a procedure itself which is becoming increasingly complex. The landmark case
Montgomery v Lanarkshire Health Board
23
demonstrated the importance of patient discussions as the medical consent process moves towards a more patient-centred method of consent in which the 'material risks' involved in a treatment and reasonable alternatives must be discussed with the patient or parent to allow them to attach appropriate personal significance to risk. This marked change from the risks perceived by the 'reasonable doctor' to the 'reasonable patient' puts extra emphasis on the need for greater discussion and information availability for patients. In the context of the potentially complex ethical issues arising from biobanks, and with the added complexity of minor consent, it is perhaps understandable that tissue donation consent is often omitted or given low priority owing to time pressures.
Behavioural change approach can be a cost-effective method to increase consent for biobanking, but we recognise from our study that further improvement can be made. More effort can be made to ensure clinicians ask all patients who may require histological investigation and to spend enough time to gain informed consent. Administrative issues such as ensuring that the patient consent form accompanies all tissue specimens has limited valid biobanking samples.
CONCLUSION
Integrated networks of biobanks are an effective way to share biological specimens and data for basic science and translational research. This is of great value in advancing our understanding of rare diseases and to further delineate the full spectrum of more common pathologies. Educating surgeons on the importance of biobanking can help patients and families to decide whether to donate tissue for research by optimising informed consent. This is particularly important as the rate of declining tissue for biobanking by patients and parents is low. Resource and time pressures are recognised barriers. Education and behaviour modification can help clinicians to adapt and incorporate biobanking as part of their routine practice during procedural consent, which will ultimately increase the numbers of biobank specimens available to contribute towards research.
